[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cardio-oncology\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cardio-oncology":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,59,95,123],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":35,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":58},"100587602","judicious-surveillance-for-trastuzumab-induced-cardiotoxicity-in-the-first-year-100587602",false,"NCT06930521","JUdicious Surveillance for Trastuzumab Induced Cardiotoxicity in the First Year","JUdicious Surveillance for Trastuzumab Induced Cardiotoxicity in the First Year (JUSTIFY): a Randomized Controlled Trial","JUSTIFY","Inclusion Criteria:\n\n1. Stage 1-3 breast cancer (BC).\n2. Age 18-79 years.\n3. HER-2 positive BC with planned HER2 targeted therapy (HER2TT) for curative intent.\n\nExclusion Criteria:\n\n1. Distant metastases detected clinically, radiographically, or histologically\n2. Baseline echocardiogram images of insufficient quality for a quantitative assessment of left ventricular ejection fraction (LVEF)\n3. Pre-existing cardiovascular disease, defined as:\n\n   1. Prior myocardial infarction (even if LVEF has normalized)\n   2. Prior heart failure (HF, including patients with preserved ejection fraction and normalized LVEF)\n   3. Baseline LVEF \\\u003C55%\n   4. Atrial fibrillation\n   5. Greater than moderate valvular disease (i.e., severe, or moderate-severe)\n4. Cumulative anthracycline exposure ≥250mg\u002Fm2 before starting HER2TT\n5. New York Heart Association Functional Class II, III or IV, or Eastern Cooperative Oncology Group score \\>2\\*\n6. Symptoms potentially due to serious cardiac disease as per investigator's judgement\\* \\*Exclusion criterion adopted as they make clinical assessment less reliable to detect emergent HF.","ALL","18 Years","79 Years",{"count":21,"type":22},300,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study focuses on male and female patients being treated for breast cancer that is positive for the HER2 receptor which requires special treatments targeting that receptor. The problem is that these treatments, while effective for the cancer, can sometimes harm the heart. Because of this, patients have to undergo heart tests every three months during treatment, even if they have no history of heart disease or feel fine.\n\nThe guidelines for these regular heart tests were established decades ago when these treatments were first introduced, but research shows that most of these tests don't actually change the treatment plan. This suggests that many patients are going through unnecessary tests, which can cause stress, delay treatments, and increase healthcare costs.\n\nTo address this, the researchers propose a new study with 300 patients with HER2 positive breast cancer to test a more personalized approach to cardiac surveillance. Participants will be classified based on their risk of heart problems: low or intermediate. Instead of testing every patient every three months, those in the intermediate group will be tested every 4 months, and those in the low-risk group will be tested every 6 months. The researchers will compare this new approach to the current system to see if fewer tests are just as safe and effective.\n\nThe researchers will measure heart health, how well cancer treatments are completed, and how patients feel about having fewer tests. If this new approach works, it could save money and reduce the burden on female patients without risking their health.",[28,29,30,31,32,33,34],"Cardiovascular Health","Breast Cancer","Breast Cancer Early Stage Breast Cancer (Stage 1-3)","Cardio-oncology","Circulatory and Respiratory Health","Clinical and Translational Cardiovascular Sciences","Health Services and Systems - Healthcare Effectiveness &Amp; Outcomes",[36,37,38,39,40,41,42,43,44,45],"Trastuzumab","Cardiac imaging","Her-2 positive breast cancer","Echocardiography","Cardiotoxicity","Left ventricular ejection fraction","Heart failure","Randomized controlled trial","Nuclear imaging","Non-inferiority","RECRUITING","2026-06-11",{"date":49,"type":50},"2026-06-15","ACTUAL",{"date":52,"type":50},"2026-04-22",{"date":54,"type":22},"2033-06",{"name":56,"class":57},"Women's College Hospital","OTHER",1,{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":11,"sex":17,"minAge":67,"maxAge":4,"enrollmentInfo":68,"targetDuration":4,"studyType":23,"phases":70,"briefSummary":71,"conditions":72,"keywords":77,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":58},"100640884","structured-cardio-oncology-rehabilitation-for-cardiovascular-outcomes-in-cancer-survivors-100640884","NCT07622394","Structured Cardio-Oncology Rehabilitation for Cardiovascular Outcomes in Cancer Survivors","A Multicenter, Prospective, Parallel-Group, Superiority Randomized Controlled Trial of Structured Cardio-Oncology Rehabilitation for Improving Cardiovascular Outcomes in Patients With Cancer Therapy-Related Cardiac Dysfunction or High Cardiovascular Risk","CORE-CTRCD","Inclusion Criteria:\n\n* Age 18 years or older, regardless of sex.\n* Histologically or cytologically confirmed solid tumor or hematologic malignancy.\n* Completed curative anti-cancer therapy, or receiving stable adjuvant, maintenance, or palliative anti-cancer therapy.\n* Meets at least one criterion for cancer therapy-related cardiac dysfunction (CTRCD) or high cardiovascular risk, including reduced LVEF after anti-cancer therapy, high-dose anthracycline exposure, chest radiotherapy with cardiovascular risk factors, heart failure after anti-cancer therapy, or elevated cardiac injury\u002Fheart failure biomarkers.\n* Estimated life expectancy of at least 24 months as assessed by the treating oncologist.\n* Able to complete baseline cardiopulmonary exercise testing and has no absolute contraindication to exercise training.\n* Able and willing to provide written informed consent and comply with study intervention and follow-up.\n\nExclusion Criteria:\n\n* Active progressive malignancy requiring urgent anti-cancer therapy, or estimated life expectancy less than 24 months.\n* Severe structural heart disease, including severe valvular disease, congenital heart disease, end-stage heart failure, or waiting for heart transplantation or left ventricular assist device implantation.\n* Absolute contraindications to exercise training, including uncontrolled malignant arrhythmia, acute myocarditis or pericarditis, acute coronary syndrome within 2 weeks, severe anemia, severe thrombocytopenia or neutropenia, uncontrolled hypertension, active infection, or severe musculoskeletal disease preventing exercise training.\n* Participation in a structured cardiac rehabilitation program within the previous 12 months, or regular moderate-to-vigorous aerobic or resistance training for at least 3 months before enrollment.\n* Implanted ICD or CRT, except pacemakers with exercise mode.\n* Severe psychiatric disease or cognitive impairment preventing participation.\n* Concurrent participation in another interventional clinical trial, or planned participation in another interventional clinical trial during the study period.\n* Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.","18 Months",{"count":69,"type":22},800,[25],"Cancer therapy-related cardiac dysfunction (CTRCD) has become a major cause of morbidity and mortality among cancer survivors. Although cardiac rehabilitation is recommended for cardiovascular disease prevention and management, high-quality randomized controlled evidence regarding its efficacy in cardio-oncology populations remains limited.\n\nThis multicenter, prospective, parallel-group, superiority randomized controlled trial aims to evaluate whether a structured cardio-oncology rehabilitation (CORE) program combined with usual care can improve cardiovascular outcomes in patients with CTRCD or cancer survivors at high cardiovascular risk, compared with usual care alone.\n\nA total of 800 participants will be randomized in a 1:1 ratio to receive either structured cardio-oncology rehabilitation plus usual care or usual care alone. The intervention includes individualized exercise training, nutritional management, psychosocial support, cardiovascular risk-factor optimization, and patient education. Participants will be followed for 12 months.\n\nThe primary endpoint is time to first major adverse cardiovascular event (MACE) within 12 months. Secondary endpoints include changes in cardiorespiratory fitness, cardiac function, biomarkers, quality of life, physical function, psychological status, safety outcomes, and health economic outcomes.",[73,31,74,75,76],"Cancer Therapy-Related Cardiac Dysfunction","Cancer Survivorship","Cardiovascular Risk","Heart Failure",[78,79,80,81,82,83,84],"Structured Cardio-Oncology Rehabilitation","Cardiac Rehabilitation","Cancer Survivors","Major Adverse Cardiovascular Events","Exercise Training","Cardiorespiratory Fitness","CTRCD","NOT_YET_RECRUITING","2026-06-02",{"date":88,"type":50},"2026-06-03",{"date":90,"type":22},"2026-09-01",{"date":92,"type":22},"2029-09-30",{"name":94,"class":57},"Xinjiang Medical University",{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":104,"phases":4,"briefSummary":105,"conditions":106,"keywords":109,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":58},"100539901","immune-checkpoint-inhibitor-therapy-for-cancer-and-risk-of-myocarditis-or-cardiomyopathy-100539901","NCT06309862","Immune Checkpoint Inhibitor Therapy for Cancer and Risk of Myocarditis or Cardiomyopathy","Association of Immune Checkpoint Inhibitor Therapy for Cancer With Early Myocardial Tissue and Biomarker Changes During Treatment - Implication for Risk of Myocarditis and Cardiomyopathy","Inclusion Criteria:\n\n* All patients 18 years of age, or older, with skin cancer and eligible for ICI treatment with a combination of a) nivolumab, b) pembrolizumab, or c) ipilimumab.\n* Able to provide informed consent\n* Able to travel to SHSC for cardiac imaging.\n\nExclusion Criteria:\n\n* Life expectancy equal to, or less than, 12 months\n* Participating in another clinical trial\n* Treated with ICI in the past\n* History of cardiac disease (e.g. heart failure, myocardial infarction, atrial fibrillation, unstable angina)\n* Pregnant patients\n* Impaired renal function (GFR equal to, or less than, 30mL\u002Fmin)\n* Contraindications for MRI (e.g. pacemaker).",{"count":103,"type":22},15,"OBSERVATIONAL","Patients undergoing dual treatment with Immune checkpoint inhibitors (ICI) for various cancers, e.g. melanoma, are at increased risk of developing myocarditis and cardiomyopathy. Currently, only limited data on serial myocardial tissue changes during treatment and whether they predict outcomes are available. Cardiac MRI (CMR) is the reference standard for non-invasive myocardial volumes\u002Ffunction analysis and uniquely characterizes myocardial tissue. Therefore, it may help detect myocardial tissue changes during treatment and help early treatment and prevent adverse cardiac outcomes.",[107,108],"Cardio-Oncology","Cardiomyopathy Due to Drug",[107,110,111,112,113],"Immunotherapy","Cardiomyopathy","Cardiac MRI","Myocardial tissue changes","2024-06-06",{"date":116,"type":50},"2024-06-07",{"date":118,"type":22},"2024-06-01",{"date":120,"type":22},"2025-12-31",{"name":122,"class":57},"Sunnybrook Health Sciences Centre",{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":131,"enrollmentInfo":132,"targetDuration":133,"studyType":104,"phases":4,"briefSummary":134,"conditions":135,"keywords":139,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":58},"100539345","cardio-oncology-rehabilitation-care-process-100539345","NCT06302634","Cardio-Oncology Rehabilitation Care Process","Hospital-based Cardio-Oncology Rehabilitation Care Process for Cardiovascular Health in Cancer Patients","ReCO","Inclusion Criteria:\n\n* High risk of cancer treatment-related cardiotoxicity\n* Possibility of completing a cardio-onco rehabilitation program (centre-based or home-based) and programmed visits.\n* Providing written informed consent.\n\nExclusion Criteria:\n\n* Patients with physical or mental limitation to carry out an exercise program.","70 Years",{"count":21,"type":22},"9 Months","The objective of this observational study is to assess the outcomes of a hospital-based Cardio-Oncology Rehabilitation (CORe) program focused on exercise in cancer patients undergoing cardiotoxic treatment. This evaluation will be conducted by analyzing disease-related health indicators, functional capacity, and quality of life. Patients at risk of cardiotoxicity attending the Cardio-Onco-Hematology Unit will be offered the exercise program, which includes two modalities: in-person (center-based) and remote (home-based) options. The assignment to either modality is non randomized, based on the functional assessment conducted in the Rehabilitation Unit and the agreement between healthcare professional and patient. All participants will perform a 3-month supervised exercise intervention. There are 3 time points for assessment: at baseline (T0), 3-month after the exercise program (T1) and follow-up at 9 months from baseline (T2).",[107,136,137,138],"Rehabilitation","Cardiovascular Diseases","Exercise",[140],"cardio-oncology rehabilitation; cardiovascular prevention; exercise; cancer","2024-03-13",{"date":143,"type":50},"2024-03-15",{"date":145,"type":50},"2022-06-22",{"date":147,"type":22},"2027-06-22",{"name":149,"class":57},"Hospital Clinico Universitario de Santiago"]